Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• Bank Hapoalim purchased 19,640 shares of Edwards Lifesciences in the second quarter, representing an investment of approximately $1.78 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain generally positive, with 17 Buy ratings and six Holds, producing a consensus rating of “Moderate Buy” and an average price target of $100.27.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in earnings per share versus a $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. Shares opened at $91.51, while company insiders have sold 26,190 shares worth about $2.27 million over the past three months.

Bank Hapoalim BM purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,640 shares of the medical research company's stock, valued at approximately $1,777,000.

A number of other large investors have also recently modified their holdings of EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $266,000. NewEdge Advisors LLC raised its stake in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock valued at $2,787,000 after purchasing an additional 2,665 shares in the last quarter. Sei Investments Co. lifted its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC lifted its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its stake in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after buying an additional 1,065 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on EW shares. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Barclays reaffirmed an "overweight" rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Mizuho upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Robert W. Baird increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday, April 24th. Finally, UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target on the stock. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business's stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company's stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 26,190 shares of company stock valued at $2,269,697. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 1.1%

Shares of EW opened at $91.51 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market cap of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85. The firm has a 50 day moving average price of $88.73 and a 200-day moving average price of $84.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source